dc.contributor.author |
Joone, C.J. (Carolynne)
|
|
dc.contributor.author |
Schulman, M.L. (Martin)
|
|
dc.contributor.author |
Bertschinger, Hendrik Jan
|
|
dc.date.accessioned |
2017-01-30T06:30:07Z |
|
dc.date.issued |
2017-02 |
|
dc.description.abstract |
Despite more than 40 years of research into zona pellucida (ZP)–based vaccines, relatively
little is known about their mechanism of action. Early research demonstrated precipitation
of ZP glycoproteins by antiovarian antiserum, rendering oocytes resistant to sperm binding
in vitro. Subsequent work showed significantly decreased fertilization rates following
passive immunization, sparking interest in anti-ZP immunocontraception for human and
animal use. The primary mechanism of action of ZP vaccines is generally considered to be
an antibody-mediated interference with sperm–oocyte binding and/or fertilization.
However, this mechanism of action excludes the potential for ovarian dysfunction associated
with anti-ZP treatment in some species. A review of relevant literature in pertinent
model, domestic and wildlife species reveals a variety of previous and current hypotheses
for ovarian effects following ZP-based immunization. Ovarian dysfunction has been suggested
to be a species-specific response. In addition, cytotoxic T-lymphocytes and the use
of Freund’s adjuvants have been suggested to play a role. Finally, the type and extent of
glycosylation of ZP antigens have been proposed to influence ovarian effects. The validity
of these hypotheses is re-examined in the light of current knowledge. Further investigation
of ovarian function in species believed to be resistant to the ovarian effects of anti-ZP
vaccines is warranted. To this end, anti-Müllerian hormone may provide a novel tool for
the assessment of ovarian function during ZP-based immunocontraception, particularly in
wildlife species not amenable to frequent clinical examination |
en_ZA |
dc.description.department |
Production Animal Studies |
en_ZA |
dc.description.embargo |
2018-02-28 |
|
dc.description.librarian |
hb2017 |
en_ZA |
dc.description.uri |
http://www.theriojournal.com |
en_ZA |
dc.identifier.citation |
Joone, CJ, Schulman, ML & Bertschinger, HJ 2017, 'Ovarian dysfunction associated with zona pellucida–based immunocontraceptive vaccines', Theriogenology, vol. 89, pp. 329-337. |
en_ZA |
dc.identifier.issn |
0093-691X (print) |
|
dc.identifier.issn |
1879-3231 (online) |
|
dc.identifier.other |
10.1016/j.theriogenology.2016.09.018 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/58675 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Elsevier |
en_ZA |
dc.rights |
© 2016 Elsevier Inc. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Theriogenology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Theriogenology, vol. 89, pp. 329-337, 2017. doi : 10.1016/j.theriogenology.2016.09.018. |
en_ZA |
dc.subject |
Porcine zona pellucida |
en_ZA |
dc.subject |
Contraception |
en_ZA |
dc.subject |
Anestrus |
en_ZA |
dc.subject |
Oophoritis |
en_ZA |
dc.subject |
Freund’s adjuvant |
en_ZA |
dc.subject |
Cytotoxic T-lymphocyte |
en_ZA |
dc.subject |
Zona pellucida (ZP) |
en_ZA |
dc.title |
Ovarian dysfunction associated with zona pellucida–based immunocontraceptive vaccines |
en_ZA |
dc.type |
Postprint Article |
en_ZA |